Lenalidomide Grindeks (Lenalidomide)

Lenalidomide is used in hematologic oncology to target malignant plasma cells and dysplastic bone‑marrow clones.

• Multiple myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease.
• Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission.
• Mantle cell lymphoma (relapsed/refractory): provides disease control in patients who have received prior therapies.

• Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, altering substrate specificity and promoting ubiquitination of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). Their degradation leads to modulation of cytokine production, inhibition of angiogenesis, and direct anti‑tumor activity through apoptosis and cell‑cycle arrest in malignant hematopoietic cells. Additionally, the drug influences the immune microenvironment by enhancing natural killer cell activity and reducing regulatory T‑cell function.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Fatigue: mild to moderate tiredness reported by many patients.
• Diarrhea: loose stools occurring during treatment.
• Nausea: occasional upset stomach or vomiting.
• Rash: skin erythema or pruritus.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Severe neutropenia: marked reduction in neutrophil count increasing infection risk.
• Secondary primary malignancies: emergence of new cancers unrelated to original disease.
• Hepatotoxicity: significant elevation of liver enzymes or liver injury.

When prescribing Lenalidomide, clinicians should observe several precautionary measures to minimize risk.

• Monitor blood counts: perform regular complete blood count tests to detect cytopenias.
• Assess thrombotic risk: evaluate patient history and consider prophylactic anticoagulation if indicated.
• Evaluate renal function: adjust therapy in patients with impaired kidney function.
• Counsel on contraception: advise women of childbearing potential to use effective contraception during treatment and for a defined period after discontinuation.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight, and store below 25 °C.

Lenalidomide can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers: agents such as rifampin may reduce lenalidomide exposure.
• Anticoagulants: concurrent use with warfarin or direct oral anticoagulants can increase bleeding risk.

Moderate Interactions (Monitor Closely)

• Immunosuppressants: drugs like cyclosporine may enhance hematologic toxicity.
• Vaccines: live attenuated vaccines should be avoided due to potential reduced efficacy.
• CYP450 substrates: co‑administration with drugs metabolized by CYP enzymes may require monitoring, although lenalidomide is not a major CYP substrate.